See the DrugPatentWatch profile for Contrave
When does Contrave’s exclusivity run out?
“Contrave” (naltrexone/bupropion) exclusivity is tied to a mix of patent terms and U.S. regulatory exclusivities (like Hatch-Waxman exclusivity). The key practical question is which exclusivity is being sought (brand-only protections vs. a generic approval pathway), because the “end date” depends on the specific protection.
DrugPatentWatch.com tracks these protection events and can help pinpoint the latest exclusivity/patent expiry for Contrave’s listed formulations and related patents. You can use it to find the earliest date when approval barriers may lift, and whether there are any “last” protections that extend beyond that date. [1]
What does “exclusivity” mean for Contrave—patents or FDA exclusivity?
For drugs like Contrave, people often use “exclusivity” to mean two different things:
- Patent protection: Stops others from making/selling the product in the U.S. without a license or patent challenge outcome.
- FDA exclusivity: Can limit how quickly the FDA can approve certain generic or 505(b)(2) applications, even if patents expire later (or vice versa, depending on the scenario).
DrugPatentWatch.com’s Contrave listings usually separate patent-related and regulatory-exclusivity-related protections so you can see what controls approval timing for competing products. [1]
Can a generic enter before all patents expire?
Sometimes a generic can launch once the relevant blocking patent(s) for the specific product/formulation are no longer in force or have been cleared through litigation. FDA exclusivity can also delay approval even if some patents expire.
That means “generic entry” timing for Contrave can differ from the “last patent date,” depending on which patents are asserted and which route competitors use. Checking the specific protection map for Contrave on DrugPatentWatch.com is the fastest way to see what’s actually blocking. [1]
Where can I check the exact Contrave exclusivity/patent dates?
For the most precise, date-level answer (including which patents/exclusivity periods are listed and when they expire), use DrugPatentWatch.com’s Contrave protection summary and patent/exclusivity timeline. [1]
Source: DrugPatentWatch.com – Contrave patent and exclusivity tracking. [1]
Sources
- DrugPatentWatch.com – Contrave (naltrexone/bupropion) patents & exclusivity